Atmo Biosciences is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule.

Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels.

Atmo Biosciences has closed a successful, oversubscribed A$9.6m capital raise.

The raise was led by two new, cornerstone investors – Sydney-based investment firm Alium Capital Management and Japanese multinational company Otsuka Pharmaceutical.

Atmo Biosciences CEO Mal Hebblewhite was invited to present at Medical Director’s Healthtech Showcase.

A Monash University comparative study has found Atmo Biosciences’ novel ingestible gas-sensing capsule to be similar to a validated wireless motility capsule (WMC) when assessing regional gastrointestinal transit time in healthy adults.

Atmo Biosciences has been awarded a Victorian Government Technology Adoption and Innovation Program (TAIP) grant to support the software development for the Atmo Gas Capsule.

Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule.

Prime Minister Scott Morrison and Member for Chisholm Gladys Liu met with Atmo Biosciences CEO Malcolm Hebblewhite during a visit to Atmo’s manufacturing partner Planet Innovation last week.

Preliminary results of a study comparing Atmo Biosciences’ novel ingestible gas-sensing capsule with a validated wireless motility capsule indicate that the Atmo capsule is a safe and promising tool to assess gut transit time.

Data from the Monash University comparative study, led by Professor Peter Gibson, was presented in a poster at the Meeting of the Federation of Neurogastroenterology & Motility (FNM 2020), held in Adelaide last week.